The strong IMCIVREE launch in acquired HO and EU approval are positive catalysts, but the EMANATE trial failure and widening losses create uncertainty. Watch for PMDA decision in H2 2026 and upcoming data readouts from PWS and RM-718 trials. The stock may trade on execution of the HO launch ramp rather than near-term profitability.
Price Chart
Executive Summary
Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1M (up 59% YoY from $37.7M) and GAAP EPS of -$0.83, beating consensus estimates of -$0.86. The U.S. launch of IMCIVREE for acquired hypothalamic obesity is off to a strong start with >150 patient start forms in the first six weeks, and European Commission marketing authorization was granted in May 2026. However, net loss widened to -$56.7M from -$50.8M, and the Phase 3 EMANATE trial failed its primary endpoint, tempering the overall outlook.
Key Financial Metrics
Key Facts
- Q1 2026 net product revenue of $60.1M, up 59% YoY from $37.7M
- GAAP EPS of -$0.83 vs consensus -$0.86 (3.6% beat)
- Net loss attributable to common stockholders widened to -$56.7M from -$50.8M YoY
- U.S. launch of IMCIVREE for acquired HO: >150 patient start forms in first 6 weeks post-FDA approval (March 19, 2026)
- European Commission granted marketing authorization for IMCIVREE in acquired HO on May 1, 2026
- Phase 3 EMANATE trial did not achieve primary endpoint in any of four substudies
- Cash, cash equivalents and short-term investments of $340.6M as of March 31, 2026
- 2026 Non-GAAP operating expense guidance of $385M-$415M
- Japanese NDA for setmelanotide in acquired HO under PMDA review, decision expected H2 2026
Financial Impact
Revenue growth of $22.4M YoY (+59%) driven by IMCIVREE sales; net loss increased by $5.9M YoY
Risk Factors
- Phase 3 EMANATE trial failure in genetically caused MC4R pathway diseases limits pipeline optionality
- Net loss widening and increasing SG&A expenses ($63.6M vs $39.1M YoY) pressure cash runway despite $340.6M position
- Dependence on acquired HO launch success for revenue growth; competitive and reimbursement risks
- Japanese PMDA decision and EU country-level launches subject to regulatory and commercial uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-030136 |
| Document: 0001628280-26-030136-index-headers.html | 0001628280-26-030136 |
| Document: 0001628280-26-030136-index.html | 0001628280-26-030136 |
| Document: 0001628280-26-030136.txt | 0001628280-26-030136 |
| 8-K Data (Synthetic) | 0001628280-26-030136 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | 144 | $96.77 $99.27 | ▼ −2.58% | ▼ −0.47% | $93.68 (+3.19%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▲ +1.65% | ▲ +1.45% | $93.68 (+18.72%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▼ −1.65% | ▼ −1.45% | $93.68 (−18.72%) |
Aug 4, 2026 8w ago | 8-K | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Aug 4, 2026 8w ago | Press Release | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Jul 8, 2026 12w ago | Press Release | $115.48 $106.09 | ▼ −8.13% | ▼ −8.00% | $93.68 (−18.88%) |
Jun 22, 2026 14w ago | 144 | $106.19 $110.04 | ▲ +3.63% | ▲ +2.61% | $93.68 (−11.78%) |
Jun 15, 2026 15w ago | 8-K | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 15, 2026 15w ago | Press Release | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 13, 2026 15w ago | Press Release | $89.70 $101.39 | ▲ +13.03% | ▲ +14.42% | $93.68 (+4.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access